Clinical trials: Healthy Volunteer, Type 2 Diabetes
Type II Diabetes Mellitus
Pharmacokinetics and Safety/Tolerability of CKD-379
A study to compare the pharmacokinetics and safety/tolerability between CKD-379 tablet and D759, D745, D150 combination
- Trial name
- NCT05719155
- Testing
- CKD-379, D759+D745+D150
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Type 2 Diabetes Mellitus
Bioequivalence Study of Fixed Dose Combination of 2.5 mg Saxagliptin/850 mg Metformin Tablet Relative to 2.5 mg Onglyza and 850 mg Glucophage Tablets Co-Administered
To demonstrate bioequivalence of a 2.5 mg saxagliptin/850 mg metformin fixed dose combination (FDC) tablet relative to the 2.5 mg saxagliptin tablet and 850 mg metformin (Glucophage Marketed by Merck-Serono) tablet…
- Trial name
- NCT01068743
- Testing
- saxagliptin, metformin, saxagliptin + metformin (FDC tablet)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus, Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)
Lipid and Glycogen Metabolism in Patients With Impaired Glucose Tolerance and Calcium Sensing Receptor Mutations
Background: Type 2 diabetes mellitus is a main risk factor for cardiovascular disease and heart failure, in part due to diabetic cardiomyopathy.
- Conditions
- Type 2 Diabetes Mellitus, Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Familiar Hypocalcuric Hypercalcemia, Healthy Volunteers
- Trial name
- RISC_7T (NCT02023489)
- Testing
- 1H/ 13C and 31P Magnetic Resonance Spectroscopy, Meal Tolerance Test, Hyperglycemic-hyperinsulinemic clamp
- Where
- Austria
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Type 2 Diabetes Mellitus, Hepatic Impairment
Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014)
This is a study to assess the pharmacokinetics and safety of ertugliflozin (MK-8835, PF-04971729) in participants with hepatic impairment versus healthy participants.
- Trial name
- NCT02115347
- Testing
- Ertugliflozin 15 mg
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Subjects
The Acute Effect of Atorvastain on Renal Function in Patients With Type II Diabetes
We wanted to test the hypothesis that acute treatment with atorvastatin changes renal sodium excretion, glomerular filtration rate, tubular function and vasoactive hormones in patients with type II diabetes, not in treatment with…
- Trial name
- NCT00678522
- Testing
- Atorvastatin
- Where
- 2 sites in Denmark
- Volunteers
- 25 people
- Sponsor
- Regional Hospital Holstebro
Diabetes Mellitus, Type 2
Colostrum Supplements Effect on the Physical Performance and Cognitive Function
The goal of this interventional Randomized clinical is to compare the effect of colostrum pharmaceutical preparation and placebo in a sample of Iraqi participants. The main questions to answer are: 1.
- Trial name
- NCT06007430
- Testing
- Colostrum Capsule 500 mg (Colostrum® 500 mg Veg Capsules, nowfoods®, Illinois, USA)
- Where
- Iraq
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Al-Mustafa University College
Type 2 Diabetes
Food-Effect Bioavailability Study of FDC(Gemigliptin/Metformin HCl Sustained Release) 50/1000mg(25/500mg x 2tablets)
This study is designed to investigate the food-effects on FDC(gemigliptin/metformin HCl sustained release) 50/1000mg(25/500mg x 2tablets)
- Trial name
- NCT01747083
- Testing
- FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mg x 2tablets))
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Type II Diabetes Mellitus
Study to Evaluate the Food Effect on Pharmacokinetics Profile and Safety of CKD-393
Study to evaluate the food effect on pharmacokinetic profiles and safety of CKD-393 in healthy volunteers
- Trial name
- NCT05274880
- Testing
- CKD-393
- Where
- South Korea
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Diabetes Mellitus, Type 2, Dyslipidemias
BE Study of Bilayer Combination of Gemigliptin/Rosuvastatin 50/20mg in Comparison to Monolayer Combination.
To evaluate and compare PK/PD, safety and tolerability of monolayer combination of Gemigliptin/Rosuvastatin 50/20mg and bilayer combination of Gemigliprin/Rosuvastatin 50/20mg in healthy adults.
- Trial name
- NCT03867942
- Testing
- Monolayer group, Bilayer group
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- LG Chem
Diabetes Mellitus, Type 2
Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of SRT2104 Administered to Normal Healthy Male Volunteers
The purpose of this study is to assess the pharmacokinetic profile, safety, and tolerability of SRT2104 following administration of single and multiple oral doses (once a day for seven days) at a single dose level (2.0 g/day) to…
- Trial name
- NCT00933062
- Testing
- SRT2104
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
Evaluation of Food Effect on the Pharmacokinetics of Sustained Release Metformin in Healthy Indian Volunteers
Metformin hydrochloride in its immediate release (IR) form has been successfully used for decades in the treatment of type 2 diabetes; however the IR formulation may be associated with gastrointestinal side effects (especially…
- Trial name
- NCT01561976
- Testing
- Metformin hydrochloride prolonged release, Metformin hydrochloride sustained release/Glimepiride
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
OXEMET™ 1000 mg Coated Tablets (Metformin Hydrochloride) Bioequivalence Study. OXEMET (TM) is a Trademark of the GlaxoSmithKline Group of Companies. GLAFORNIL(TM) is a Trademark of Merck.
This is an open-label, single-center, randomized, 2-way crossover study to evaluate the bioequivalence of OXEMET™ 1000 mg coated tablets, relative to 1000 mg of the reference product administered as two 500 mg tablets, under…
- Trial name
- NCT01842620
- Testing
- Metformin
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Subjects
Effect of Oat Compounds on Postprandial Glucose Response
In this project we will investigate synergistic effects of oat polar lipids and beta glucans on postprandial glucose tolerance
- Trial name
- NCT05177172
- Testing
- High beta glucans, Low beta glucans, Low beta glucans + low polar lipids
- Where
- Sweden
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Lund University
Type 1 Diabetes, Type 2 Diabetes
A Trial of 18F-AV-133 Positron Emission Tomography (PET)
The purpose of this study is to evaluate the safety and pancreas imaging properties of 18F-AV-133.
- Trial name
- NCT01515384
- Testing
- 18F-AV-133
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
A Study of the Effects of GSK189075 on PK Profiles of an Oral Contraceptive Pill When Given to Healthy Female Volunteers
The purpose of this research study is to demonstrate a lack of effect of multiple doses of GSK189075 on the PK of an oral contraceptive pill in healthy female subjects.
- Trial name
- NCT00504816
- Testing
- GSK189075, Brevicon
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteers
A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
The purpose of this study is to assess the bioequivalence of the fixed dose combination (two components combined in one tablet) of canagliflozin and metformin extended release (XR) tablet (dose of 2 X 50 mg/500 mg) with respect…
- Trial name
- NCT02065752
- Testing
- Canagliflozin, 100 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 50 mg/500 mg
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Diabetes Mellitus, Type 2
Omarigliptin & Trelagliptin in Twelve Healthy Egyptian Volunteers
The proposed study will consider the LC-MS/MS quantitative determination of Omarigliptin \& Trelagliptin after administration to twelve Egyptian volunteers.
- Trial name
- NCT03362398
- Testing
- Omarigliptin 25 mg, Trelagliptin 100 mg
- Where
- Egypt
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- British University In Egypt
Incretin Effect
Quantification of the Incretin Effect in Healthy Subjects and Patients With Type 2 Diabetes
Patients with T2DM lac a sufficient incretin response after oral glucose intake. It has only been tested using 50g of glucose. We don't know if patients with T2DM are capable of regulating the incretin effect like healthy people…
- Trial name
- NCT00529048
- Testing
- Oral Glucose Tolerance Test, Isoglycemic clamp, Gastric emptying rate
- Where
- Denmark
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Herlev Hospital
Type 2 Diabetes
A Study of PATAS Using Single Ascending Doses in Healthy Volunteers and Multiple Ascending Doses in Diabetic Subjects
This is 2-part study. The primary objective of Part 1 is to evaluate safety and tolerability of single subcutaneous (SC) doses of PATAS in healthy subjects.
- Trial name
- NCT07223333
- Testing
- PATAS Trifluoroacetate
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- AdipoPharma LLC
Type 2 Diabetes Mellitus
Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of DA-1229 and Metformin After Oral Administration in Healthy Male Subjects
This is a randomized, open-label, multiple dosing, three-way crossover clinical trial to investigate the pharmacokinetic/pharmacodynamic drug-drug interaction of DA-1229 5 mg and Metformin IR 1000 mg after oral administration in…
- Trial name
- NCT01941199
- Testing
- DA-1229, metformin, DA-1229 + metformin
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Dong-A Pharmaceutical Co., Ltd.